TCM

TCM Group reported Q2 2026 revenue up 7.4% to DKK 375m, with organic growth only 0.6%. Adjusted EBITDA fell to DKK 32.2m and the margin dropped from 10.3% to 8.6%, weighed down by a 23% rise in operating costs and a higher share of third‑party revenue. Management confirmed the full‑year guidance but recorded improved free cash flow in the first half; the stock fell 2.87% to $67.8. » Más en de.investing.com

TCM Group increased revenue in the third quarter of 2025 by 4.1% to DKK 289 million and kept adjusted EBIT at DKK 17 million, causing the EBIT margin to fall from 6.0% to 5.8%. The share price fell 0.61% after the release. TCM is acquiring the remaining 55% of Celebat to strengthen its digital presence and confirms 2025 guidance of DKK 1.26–1.28 billion in revenue and adjusted EBIT of DKK 93–100 million. » Más en de.investing.com

TCM Group A‑S invites investors to a financial conference on 25.11.2025 and will publish figures for the quarter ending 30.09.2025. One analyst forecasts an EPS of 1.26 DKK versus 0.84 DKK a year earlier; three analysts see revenue rising by 5.88% to an average of 294.0 million DKK. For the fiscal year, three analysts on average expect an EPS of 6.30 DKK and revenue of 1.28 billion DKK, compared with 5.52 DKK and 1.21 billion DKK in the prior year. » Más en finanzen.net